Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Black Diamond Therapeutics Inc (NQ: BDTX )

2.500 +0.070 (+2.88%)
Streaming Delayed Price Updated: 11:34 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 163,079
Open 2.450
Bid (Size) 2.490 (1)
Ask (Size) 2.500 (4)
Prev. Close 2.430
Today's Range 2.400 - 2.545
52wk Range 2.155 - 7.660
Shares Outstanding 36,213,654
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire

Performance

YTD
-14.09%
-14.09%
1 Month
-24.47%
-24.47%
3 Month
-59.15%
-59.15%
6 Month
-47.26%
-47.26%
1 Year
+6.84%
+6.84%

More News

Read More
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Looking Into Black Diamond Therapeutic's Recent Short Interest
Via Benzinga
Black Diamond Therapeutic: Q4 Earnings Insights
Via Benzinga
Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO), Kaival Brands (NASDAQ: KAVL) among others w/Key Announcements
Via AB Newswire
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
Via Benzinga
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
From Gyre Therapeutics, Inc.
Via GlobeNewswire
BDTX Stock Earnings: Black Diamond Therapeutic Beats EPS for Q2 2024
Via InvestorPlace
Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
BDTX Stock Earnings: Black Diamond Therapeutic Beats EPS for Q1 2024
Via InvestorPlace
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Black Diamond Therapeutics Announces Changes to Board of Directors
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.